Clinically, these findings hold a crucial relevance, suggesting that Smpd3/nSMase2 and the resultant biochemical pathways driving NAFLD present as potential targets for therapeutic interventions. The gene discussed is SMPD3; the disease is metabolic dysfunction-associated steatotic liver disease.